Plain-English translation of NCT06003153 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing how semaglutide, an oral medication, affects your body's ability to control blood sugar. The researchers want to understand how this treatment works in people who have prediabetes or borderline high fasting blood sugar levels (between 100–125 mg/dL). By comparing your blood sugar response before and after taking the medication, they hope to learn more about how it helps manage blood sugar control.
While this medication is already used to treat type 2 diabetes, researchers want to better understand exactly how it works and whether it may help people at earlier stages of blood sugar problems, such as prediabetes. This knowledge could eventually help doctors identify which patients would benefit most from this treatment.
You likely qualify if…
You likely don't qualify if…
You will visit the research center twice over about two weeks. On your first visit, you'll fast overnight, have blood drawn, eat a standard meal, and have more blood samples taken over the next two hours to measure how your body handles blood sugar. Then you'll take the medication once daily for 13 days at home. On your final visit, you'll take your last dose at the center, fast, eat the same meal again, and have blood drawn multiple times to see how the medication changed your blood sugar response. In total, this involves two in-person visits and about two weeks of daily medication.
AI-generated summary from trial data · Jul 14, 2026 · Not medical advice
United States